Skip to main content

COVID-19 trial protocols

Research into COVID-19 is exploding, as it needs to, and this includes randomised trials.  Between 23rd of January and 8th March 2020 there were 382 registered COVID-19 trials. Almost all of those were in China but the virus is now global and trials will move with it.

Researchers need to know about these trials, and they need to know quickly.  

Trials are therefore implementing a new, simplified process for handling COVID-19 trial protocols which is must faster and much simpler for authors. Please visit trialsjournal.biomedcentral.com/covid-19 for more information.

Page 1 of 4

  1. Convalescent plasma has been used for numerous viral diseases including influenza, severe acute respiratory syndrome, Middle East respiratory syndrome and Ebola virus; however, evidence to support its use is w...

    Authors: Philippe Bégin, Jeannie Callum, Nancy M. Heddle, Richard Cook, Michelle P. Zeller, Alan Tinmouth, Dean A. Fergusson, Melissa M. Cushing, Marshall J. Glesby, Michaël Chassé, Dana V. Devine, Nancy Robitalle, Renée Bazin, Nadine Shehata, Andrés Finzi, Allison McGeer…

    Citation: Trials 2021 22:323

    Content type: Study protocol

    Published on:

  2. Uptake of vaccination against COVID-19 is key to controlling the pandemic. However, a significant proportion of people report that they do not intend to have a vaccine, often because of concerns they have abou...

    Authors: Ben Young, Marie Kotzur, Lauren Gatting, Carissa Bonner, Julie Ayre, Alex McConnachie, Carys Batcup, Kirsten McCaffery, Ronan O’Carroll and Kathryn A. Robb

    Citation: Trials 2021 22:311

    Content type: Letter

    Published on:

  3. This research aims to study the efficacy of tannins co-supplementation on disease duration, severity and clinical symptoms, microbiota composition and inflammatory mediators in SARS-CoV2 patients.

    Authors: Silvia Molino, Andrea Pisarevsky, Fabiana Lopez Mingorance, Patricia Vega, Juan Pablo Stefanolo, Julieta Repetti, Guillermina Ludueña, Pablo Pepa, Juan Ignacio Olmos, Marcelo Rodriguez Fermepin, Tatiana Uehara, Sonia Villapol, Tor Savidge, Todd Treangen, Elisa Viciani, Andrea Castagnetti…

    Citation: Trials 2021 22:310

    Content type: Letter

    Published on:

  4. The aim of this trial is to evaluate the antiviral efficacy, clinical efficacy, and safety of nelfinavir in patients with asymptomatic and mild COVID-19.

    Authors: Naoki Hosogaya, Taiga Miyazaki, Yuri Fukushige, Sachiko Takemori, Shinpei Morimoto, Hiroshi Yamamoto, Makoto Hori, Tomoya Kurokawa, Yohei Kawasaki, Michiko Hanawa, Yasuhisa Fujii, Hideki Hanaoka, Shingo Iwami, Koichi Watashi, Satoshi Yamagoe, Yoshitsugu Miyazaki…

    Citation: Trials 2021 22:309

    Content type: Letter

    Published on:

  5. The primary objective is to demonstrate that, in patients with PCR-confirmed SARS-CoV-2 resulting in Acute Respiratory Distress Syndrome (ARDS), administration of 120mg/kg of body weight of intravenous Prolast...

    Authors: Natalie L. McEvoy, Jennifer L. Clarke, Oliver J. Mc Elvaney, Oisin F. Mc Elvaney, Fiona Boland, Deirdre Hyland, Pierce Geoghegan, Karen Donnelly, Oisin Friel, Ailbhe Cullen, Ann M. Collins, Daniel Fraughen, Ignacio Martin-Loeches, Martina Hennessy, John G. Laffey, Noel G. Mc Elvaney…

    Citation: Trials 2021 22:288

    Content type: Letter

    Published on:

  6. The primary objective is to evaluate the efficacy of an inactivated and aluminium hydroxide adsorbed SARS-CoV-2 vaccine (Sinovac, China) in voluntary participants after 14 days of the second dose against RT-PC...

    Authors: Murat Akova and Serhat Unal

    Citation: Trials 2021 22:276

    Content type: Letter

    Published on:

  7. Severe acute respiratory infection (SARI) caused by the SARS-CoV-2 virus may cause lung failure and the need for mechanical ventilation. Infection with SARS-COV-2 can lead to activation of inflammatory factors...

    Authors: Arash Rahimi, Hamid Reza Samimagham, Mehdi Hassani Azad, Dariush Hooshyar, Mohsen Arabi and Mitra KazemiJahromi

    Citation: Trials 2021 22:271

    Content type: Letter

    Published on:

  8. The primary objective of MATIS is to determine the efficacy of ruxolitinib (RUX) or fostamatinib (FOS) compared to standard of care (SOC) with respect to reducing the proportion of hospitalised patients progre...

    Authors: Nikhil Vergis, Rachel Phillips, Victoria Cornelius, Alexia Katsarou, Taryn Youngstein, Lucy Cook, Michelle Willicombe, Clio Pilay, Tina Shturova, Melanie Almonte, Asad Charania, Richard Turner, Onn Min Kon, Graham Cooke, Mark Thursz, Svetlana Cherlin…

    Citation: Trials 2021 22:270

    Content type: Letter

    Published on:

  9. The COVID-19 related lockdowns and distancing measures have presented families with unprecedented challenges. A UK-wide cohort study tracking changes in families’ mental health since early lockdown (Co-SPACE) ...

    Authors: Katarzyna Kostyrka-Allchorne, Cathy Creswell, Sarah Byford, Crispin Day, Kimberley Goldsmith, Marta Koch, Walter Muruet Gutierrez, Melanie Palmer, Jasmine Raw, Olly Robertson, James Shearer, Adrienne Shum, Petr Slovak, Polly Waite and Edmund J. S. Sonuga-Barke

    Citation: Trials 2021 22:267

    Content type: Letter

    Published on:

  10. To examine the effectiveness of randomising dissemination of the Germ Defence behaviour change website via GP practices across England UK.

    Authors: Jeremy Horwood, Melanie Chalder, Ben Ainsworth, James Denison-Day, Frank de Vocht, Martha M. C. Elwenspoek, Pippa Craggs, Rachel Denholm, Jonathan Sterne, Cathy Rice, Sascha Miller, Beth Stuart, Paul Little, Michael Moore, Merlin Willcox, John Macleod…

    Citation: Trials 2021 22:263

    Content type: Letter

    Published on:

  11. The primary objective is to determine the effect of a daily dose of ivermectin administered in three consecutive days to non-severe COVID-19 patients with no more than 96 hours of symptoms, on the detection of...

    Authors: Patricia J. Garcia, Hansel Mundaca, Cesar Ugarte-Gil, Patricia Leon, German Malaga, Carlos Chaccour and Cesar P. Carcamo

    Citation: Trials 2021 22:262

    Content type: Letter

    Published on:

  12. This study is conducted to investigate efficacy of pomegranate juice on inflammatory biomarkers, C-reactive protein (CRP), interleukin 6(IL-6), erythrocyte sedimentation rate (ESR) and complete blood count (CB...

    Authors: Mojtaba Yousefi, Mohammadreza Sadriirani, Azizollah PourMahmoudi, Sara Mahmoodi, Bahar Samimi, Mahboobe Hosseinikia, Zaker Saeedinezhad and Seyed Bahman Panahande

    Citation: Trials 2021 22:246

    Content type: Letter

    Published on:

  13. These 2 parallel studies (K031 and K032) aim to evaluate the safety of KB109 in addition to supportive self-care (SSC) compared with SSC alone in outpatients with mild to moderate coronavirus disease 2019 (COV...

    Authors: John P. Haran, Jose C. Pinero, Yan Zheng, Norma Alonzo Palma and Mark Wingertzahn

    Citation: Trials 2021 22:245

    Content type: Letter

    Published on:

  14. The main goal of the COVIDENZA trial is to evaluate if inhibition of testosterone signalling by enzalutamide can improve the outcome of patients hospitalised for COVID-19. The hypothesis is based on the observ...

    Authors: Karin Welén, Anna K Överby, Clas Ahlm, Eva Freyhult, David Robinsson, Anna Jonsson Henningsson, Johan Stranne, Daniel Bremell, Martin Angelin, Elisabeth Lindquist, Robert Buckland, Camilla Thellenberg Carlsson, Karlis Pauksens, Anna Bill-Axelsson, Olof Akre, Cecilia Ryden…

    Citation: Trials 2021 22:209

    Content type: Letter

    Published on:

  15. To determine the effect of therapeutic anticoagulation, with low molecular weight heparin (LMWH) or unfractionated heparin (UFH, high dose nomogram), compared to standard care in hospitalized patients admitted...

    Authors: Michelle Sholzberg, Grace H. Tang, Elnara Negri, Hassan Rahhal, Lisa Baumann Kreuziger, Carlos E. Pompilio, Paula James, Michael Fralick, Musaad AlHamzah, Faris Alomran, Eric Tseng, Gloria Lim, David Lillicrap, Marc Carrier, Fionnuala Ní Áinle, Andrew Beckett…

    Citation: Trials 2021 22:202

    Content type: Letter

    Published on:

  16. Early inhibition of entry and replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a very promising therapeutic approach. Polyclonal neutralizing antibodies offers many advantages...

    Authors: Benjamin Gaborit, Bernard Vanhove, Marie-Anne Vibet, Aurélie Le Thuaut, Karine Lacombe, Vincent Dubee, Florence Ader, Virginie Ferre, Eric Vicaut, Jéremie Orain, Morgane Le Bras, Anne Omnes, Laetitia Berly, Alexandra Jobert, Pascale Morineau-Le Houssine, Karine Botturi…

    Citation: Trials 2021 22:199

    Content type: Study protocol

    Published on:

  17. The objective of this trial is to assess whether early antiviral therapy in outpatients with COVID-19 with either favipiravir plus lopinavir/ritonavir, lopinavir/ritonavir alone, or favipiravir alone, is assoc...

    Authors: Li-An K. Brown, Nick Freemantle, Judy Breuer, Hakim-Moulay Dehbi, Kashfia Chowdhury, Gemma Jones, Felicia Ikeji, Amalia Ndoutoumou, Krishneya Santhirakumar, Nicky Longley, Anna M. Checkley, Joseph F. Standing and David M. Lowe

    Citation: Trials 2021 22:193

    Content type: Letter

    Published on:

  18. The primary objective of this study is to test the hypothesis that administration of dexamethasone 20 mg is superior to a 6 mg dose in adult patients with moderate or severe ARDS due to confirmed COVID-19. The...

    Authors: Jan Maláska, Jan Stašek, František Duška, Martin Balík, Jan Máca, Jan Hruda, Tomáš Vymazal, Olga Klementová, Jan Zatloukal, Tomáš Gabrhelík, Pavel Novotný, Regina Demlová, Jana Kubátová, Jana Vinklerová, Adam Svobodník, Milan Kratochvíl…

    Citation: Trials 2021 22:172

    Content type: Letter

    Published on:

  19. To investigate if traditional Chinese medicine (TCM) auricular point acupressure (APA) can alleviate and (or) reduce the pain (including injection site pain, headache, other muscle and joint pain), fatigue, an...

    Authors: Qinwei Fu, Hui Xie, Li Zhou, Xinrong Li, Yang Liu, Min Liu, Chaoyu Wang, Xiaocen Wang, Zhiqiao Wang, Jinfan Tang, Huan Xiao, Zhiyong Xiao, Jing Zhou, Chengzhi Feng, Li Wang, Zhimin Ao…

    Citation: Trials 2021 22:162

    Content type: Letter

    Published on:

  20. The main objective of this study is to evaluate the effect of intravenous lidocaine on gas exchange and inflammation in acute respiratory distress syndrome due or not to Covid-19 pneumonia.

    Authors: Marie Muller, François Lefebvre, Marie-Line Harlay, Ludovic Glady, Guillaume Becker, Charlotte Muller, Ouafaa Aberkane, Mira Tawk, Madoé Julians, Arnaud Romoli, Stéphane Hecketsweiler, Francis Schneider, Julien Pottecher and Thiên-Nga Chamaraux-Tran

    Citation: Trials 2021 22:131

    Content type: Letter

    Published on:

  21. The primary objectives of the study are to determine the effectiveness of the Kaba Sura Kudineer (KSK) & Nilavembu Kudineer (NVK) along with standard Allopathy Treatment to compared with Placebo (Decaffeinated...

    Authors: Anurag Srivastava, Manickavasagam Rengaraju, Saurabh Srivastava, Vimal Narayan, Vivek Gupta and Rashmi Upadhayay

    Citation: Trials 2021 22:130

    Content type: Letter

    Published on:

  22. The objective of the study is to measure the efficacy of ionic-iodine polymer complex [1] for clinical and radiological improvement in coronavirus disease 2019 (COVID-19) patients.

    Authors: Sohaib Ashraf, Shoaib Ashraf, Moneeb Ashraf, Muhammad Ahmad Imran, Larab Kalsoom, Uzma Nasim Siddiqui, Iqra Farooq, Muhammad Ghufran, Romaisa Arshad Khokhar, Muhammad Kiwan Akram, Iqra Shahid, Muhammad Sohaib Ur Rehman, Rutaba Akmal, Arbaz Tahir, Ayesha Zahid, Sidra Ashraf…

    Citation: Trials 2021 22:127

    Content type: Letter

    Published on:

  23. The rapid emergence and the high disease burden of the novel coronavirus SARS-CoV-2 have created a medical need for readily available drugs that can decrease viral replication or blunt the hyperinflammatory st...

    Authors: Iwein Gyselinck, Laurens Liesenborghs, Ewout Landeloos, Ann Belmans, Geert Verbeke, Peter Verhamme, Robin Vos and W. Janssens

    Citation: Trials 2021 22:126

    Content type: Study protocol

    Published on:

    The Correction to this article has been published in Trials 2021 22:187

  24. Baricitinib is supposed to have a double effect on SARS-CoV2 infection. Firstly, it reduces the inflammatory response through the inhibition of the Januse-Kinase signalling transducer and activator of transcri...

    Authors: G. Moreno-González, A. Mussetti, A. Albasanz-Puig, I. Salvador, A. Sureda, C. Gudiol, R. Salazar, M. Marin, M. Garcia, V. Navarro, I. de la Haba Vaca, E. Coma, G. Sanz-Linares, X. Dura, S. Fontanals, G. Serrano…

    Citation: Trials 2021 22:116

    Content type: Letter

    Published on:

  25. The aim of the RAAS-COVID-19 randomized control trial is to evaluate whether an upfront strategy of temporary discontinuation of renin angiotensin aldosterone system (RAAS) inhibition versus continuation of RA...

    Authors: Mona Aflaki, Alexandria Flannery, João Pedro Ferreira, Matthew Pellan Cheng, Nadine Kronfli, Ariane Marelli, Faiez Zannad, James Brophy, Jon Afillalo, Thao Huynh, Nadia Giannetti, Amal Bessissow, Justin A. Ezekowitz, Renato D. Lopes, Andrew P. Ambrosy, Morgan Craig…

    Citation: Trials 2021 22:115

    Content type: Study protocol

    Published on:

  26. To evaluate whether a single high dose of oral cholecalciferol improves the respiratory outcomes as compared with placebo among adults COVID-19 patients at moderate risk of clinical complications.

    Authors: Javier Mariani, Carlos Tajer, Laura Antonietti, Felipe Inserra, León Ferder and Walter Manucha

    Citation: Trials 2021 22:111

    Content type: Letter

    Published on:

  27. To investigate the effectiveness and safety of homeopathic medicine Natrum muriaticum (LM2) for mild cases of COVID-19 in Primary Health Care.

    Authors: Ubiratan Cardinalli Adler, Maristela Schiabel Adler, Livia Mitchiguian Hotta, Ana Elisa Madureira Padula, Amarilys de Toledo Cesar, José Nelson Martins Diniz, Crislaine Aparecida Antonio Mestre, Katia Regina Spiller, Lidiamara Soares, Helen de Freitas Santos and Edson Zangiacomi Martinez

    Citation: Trials 2021 22:109

    Content type: Letter

    Published on:

  28. COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. At the time this clinical trial was planned, there were no available vaccine or ther...

    Authors: Elena Diago-Sempere, José Luis Bueno, Aránzazu Sancho-López, Elena Múñez Rubio, Ferrán Torres, Rosa Malo de Molina, Ana Fernández-Cruz, Isabel Salcedo de Diego, Ana Velasco-Iglesias, Concepción Payares-Herrera, Inmaculada Casas Flecha, Cristina Avendaño-Solà, Rafael Duarte Palomino, Antonio Ramos-Martínez and Belén Ruiz-Antorán

    Citation: Trials 2021 22:70

    Content type: Study protocol

    Published on:

  29. Basic and clinical studies have shown that magnesium sulphate ameliorates lung injury and controls asthma attacks by anti-inflammatory and bronchodilatory effects. Both intravenous and inhaled magnesium sulpha...

    Authors: Guitti Pourdowlat, Seyed Ruhollah Mousavinasab, Behrooz Farzanegan, Alireza Kashefizadeh, Zohreh Akhoundi Meybodi, Maedeh Jafarzadeh and Shadi Baniasadi

    Citation: Trials 2021 22:60

    Content type: Letter

    Published on:

  30. The primary objective of this study is to evaluate the therapeutic potential of hydroxychloroquine (HCQ) in the treatment of adult patients with PCR-confirmed Covid-19 infection in a primary open-care setting,...

    Authors: Petri J. Vainio, Pauliina Hietasalo, Anna-Liisa Koivisto, Susanna Kääriäinen, Jari Turunen, Mika Virtala, Jouni Vuorinen and Mika Scheinin

    Citation: Trials 2021 22:44

    Content type: Letter

    Published on:

  31. In this cluster-randomised controlled study (CoV-Surv Study), four different “active” SARS-CoV-2 testing strategies for general population surveillance are evaluated for their effectiveness in determining and ...

    Authors: Andreas Deckert, Simon Anders, Manuela de Allegri, Hoa Thi Nguyen, Aurélia Souares, Shannon McMahon, Kathleen Boerner, Matthias Meurer, Konrad Herbst, Matthias Sand, Lisa Koeppel, Tobias Siems, Lucia Brugnara, Stephan Brenner, Robin Burk, Dan Lou…

    Citation: Trials 2021 22:39

    Content type: Letter

    Published on:

  32. We aimed to test our hypothesis that traditional Japanese (Kampo) medicine, hochuekkito (Hochu-ekki-to: HET) has a preventive effect for the symptoms on COVID-19.

    Authors: Takao Namiki, Shin Takayama, Ryutaro Arita, Tadashi Ishii, Mosaburo Kainuma, Toshiaki Makino, Masaru Mimura, Tetsuhiro Yoshino, Tatsuya Nogami, Makoto Arai, Juichi Sato, Koichiro Tanaka, Hajime Nakae, Hidetoshi Igari, Yoshihito Ozawa, Yuki Shiko…

    Citation: Trials 2021 22:23

    Content type: Letter

    Published on:

  33. 1. To assess the efficacy of Mesenchymal Stromal Cells (MSC) versus a control arm as described in the primary endpoint.

    Authors: Concepción Payares-Herrera, María E. Martínez-Muñoz, Inés Lipperheide Vallhonrat, Rosa Malo de Molina, Manuel Pérez Torres, Andrea Trisan, Isabel Salcedo de Diego, Rosalía Alonso, Rocío Zafra, Trinidad Donaire, Rocío Sánchez, Juan José Rubio, Rafael F. Duarte Palomino and Cristina Avendaño Solá

    Citation: Trials 2021 22:9

    Content type: Letter

    Published on:

  34. The primary objective is to determine which of two interventions: 1) an eight week, online, home-based, supervised, group rehabilitation programme (REGAIN); or 2) a single online session of advice (best-practi...

    Authors: Gordon McGregor, Harbinder Sandhu, Julie Bruce, Bartholomew Sheehan, David McWilliams, Joyce Yeung, Christina Jones, Beatriz Lara, Jessica Smith, Chen Ji, Elaine Fairbrother, Stuart Ennis, Peter Heine, Sharisse Alleyne, Jonathan Guck, Emma Padfield…

    Citation: Trials 2021 22:8

    Content type: Letter

    Published on:

    The Correction to this article has been published in Trials 2021 22:96

  35. We will evaluate the efficacy and safety of Ivermectin in patients with mild and moderately severe COVID-19.

    Authors: Fatemeh Sadat Hosseini, Alireza Malektojari, Sara Ghazizadeh, Mehdi Hassaniazad, Parivash Davoodian, Habib Dadvand, Amin Reza Nikpoor, Sara Nikoofal-Sahlabadi, Sara Kahoori, Mojtaba Sepandi, Soheil Hassanipour and Mohammad Fathalipour

    Citation: Trials 2021 22:4

    Content type: Letter

    Published on:

  36. To investigate the efficacy and safety of repurposed antiprotozoal and antiretroviral drugs, nitazoxanide and atazanavir/ritonavir, in shortening the time to clinical improvement and achievement of SARS-CoV-2 ...

    Authors: Adeniyi Olagunju, Adeola Fowotade, Ajibola Olagunoye, Temitope Olumuyiwa Ojo, Bolanle Olufunlola Adefuye, Adeniyi Francis Fagbamigbe, Akindele Olupelumi Adebiyi, Omobolanle Ibitayo Olagunju, Olabode Taiwo Ladipo, Abdulafeez Akinloye, Babatunde Ayodeji Adeagbo, Adedeji Onayade, Oluseye Oladotun Bolaji, Christian Happi, Steve Rannard and Andrew Owen

    Citation: Trials 2021 22:3

    Content type: Letter

    Published on:

  37. Conestat alfa, a recombinant human C1 esterase inhibitor, is a multi-target inhibitor of inflammatory cascades including the complement, the kinin-kallikrein and the contact activation system. The study object...

    Authors: Pascal Urwyler, Panteleimon Charitos, Stephan Moser, Ingmar A. F. M. Heijnen, Marten Trendelenburg, Reto Thoma, Johannes Sumer, Adrián Camacho-Ortiz, Marcelo R. Bacci, Lars C. Huber, Melina Stüssi-Helbling, Werner C. Albrich, Parham Sendi and Michael Osthoff

    Citation: Trials 2021 22:1

    Content type: Letter

    Published on:

  38. With the lack of effective therapy, chemoprevention, and vaccination against SARS-CoV-2, focusing on the immediate repurposing of existing drugs gives hope of curbing the COVID-19 pandemic. A recent unbiased g...

    Authors: Cédric Annweiler, Mélinda Beaudenon, Jennifer Gautier, Romain Simon, Vincent Dubée, Justine Gonsard and Elsa Parot-Schinkel

    Citation: Trials 2020 21:1031

    Content type: Study protocol

    Published on:

  39. We aimed to test our expectation that additional administration of Traditional Chinese medicine (TCM), maxingshigan-weijing decoction, is more effective in the management of COVID-19 patients compared to those...

    Authors: Congcong Zeng, Zhengzhong Yuan, Xiaoqiong Pan, Jizhou Zhang, Jiahui Zhu, Fan Zhou, Zhuocheng Shan, Ye Yuan, Ren Ye and Jinguo Cheng

    Citation: Trials 2020 21:1029

    Content type: Letter

    Published on:

  40. This study aims to investigate the efficacy of curcumin-piperine co-supplementation on disease duration, severity and clinical symptoms, and inflammatory mediators in patients with coronavirus (COVID-19).

    Authors: Mahsa Miryan, Mohammad Bagherniya, Amirhossein Sahebkar, Davood Soleimani, Mohammad Hossein Rouhani, Bijan Iraj and Gholamreza Askari

    Citation: Trials 2020 21:1027

    Content type: Letter

    Published on:

  41. SARS-Cov-2 virus preferentially binds to the Angiotensin Converting Enzyme 2 (ACE2) on alveolar epithelial type II cells, initiating an inflammatory response and tissue damage which may impair surfactant synth...

    Authors: Ahilanandan Dushianthan, Howard Clark, Jens Madsen, Robin Mogg, Lewis Matthews, Lee Berry, Jorge Bernardino de la Serna, James Batchelor, David Brealey, Tracy Hussell, Joanna Porter, Ratko Djukanovic, Martin Feelisch, Anthony Postle and Michael P. W. Grocott

    Citation: Trials 2020 21:1014

    Content type: Letter

    Published on:

  42. This interventional study will investigate the effect of daily use of a mindfulness app on measures of participant anxiety, well-being, and perceived outlook during the COVID-19 pandemic, by comparing pre-inte...

    Authors: Katherine T. O’Donnell, Melanie Dunbar and Diana L. Speelman

    Citation: Trials 2020 21:1006

    Content type: Letter

    Published on:

  43. The peak of the global COVID-19 pandemic has not yet been reached, and many countries face the prospect of a second wave of infections before effective vaccinations will be available. After an initial phase of...

    Authors: T. Vanassche, M. M. Engelen, Q. Van Thillo, J. Wauters, J. Gunst, C. Wouters, C. Vandenbriele, S. Rex, L. Liesenborghs, A. Wilmer, P. Meersseman, G. Van den Berghe, D. Dauwe, G. Verbeke, M. Thomeer, T. Fivez…

    Citation: Trials 2020 21:1005

    Content type: Study protocol

    Published on:

    The Correction to this article has been published in Trials 2020 21:1033

  44. A severe epidemic of COVID-19 has broken out in China and has become a major global public health event. We focus on the Acute Respiratory Distress Syndrome (ARDS)-like changes and overactivation of Th17 cells...

    Authors: Panpan Liu, Zhijun Huang, Mingzhu Yin, Chun Liu, Xiang Chen, Pinhua Pan and Yehong Kuang

    Citation: Trials 2020 21:999

    Content type: Letter

    Published on:

  45. This study aims to assess the effect of propolis supplementation on clinical symptoms in patients with coronavirus (COVID-19).

    Authors: Mahsa Miryan, Davood Soleimani, Leila Dehghani, Karim Sohrabi, Farzin Khorvash, Mohammad Bagherniya, Sayed Mazaher Sayedi and Gholamreza Askari

    Citation: Trials 2020 21:996

    Content type: Letter

    Published on:

  46. Patients with COVID-19 and hypoxaemia despite conventional low-flow oxygen therapy are often treated with high-flow nasal cannula (HFNC) in line with international guidelines. Oxygen delivery by helmet continu...

    Authors: Jonas Tverring, Anna Åkesson and Niklas Nielsen

    Citation: Trials 2020 21:994

    Content type: Study protocol

    Published on:

  47. Since December 2019, the outbreak of coronavirus pneumonia was observed in China and quickly propagate in all of the world. Nowadays, many trials are underway on this disease in which the efficacy of various t...

    Authors: Maryam Azimi and Fatemeh Sadat Hasheminasab

    Citation: Trials 2020 21:978

    Content type: Study protocol

    Published on:

  48. Patients with diabetes are - compared to people without diabetes - at increased risk of worse outcomes from COVID-19 related pneumonia during hospitalization. We aim to investigate whether telemetric continuou...

    Authors: Carina Kirstine Klarskov, Birgitte Lindegaard, Ulrik Pedersen-Bjergaard and Peter Lommer Kristensen

    Citation: Trials 2020 21:968

    Content type: Letter

    Published on:

  49. To assess the efficacy of ivermectin in addition to standard treatment compared to standard treatment alone in reducing hospitalizations in the COVID-19 patient population.

    Authors: Julio Vallejos, Rodrigo Zoni, Maria Bangher, Silvina Villamandos, Angelina Bobadilla, Fabian Plano, Claudia Campias, Evangelina Chaparro Campias, Fernando Achinelli, Hector A. Guglielmone, Jorge Ojeda, Fernanda Medina, Diego Farizano Salazar, Gerardo Andino, Natalia E. Ruiz Diaz, Pablo Kawerin…

    Citation: Trials 2020 21:965

    Content type: Letter

    Published on:

\